The Russian Federation has learned to treat lymphoma three times more effectively

Medics at Sechenov University have started using a new approach to the therapy of diffuse B-cell large cell lymphoma. Using genetic analysis, the specialists managed to determine the tumor subtype.

Cell strike: in the Russian Federation they are creating a unique immune-engineered cancer drug

How a drug based on a patient's modified T cells would work

Thanks to this, they were able to prescribe personalized therapy to patients. As a result, doctors have tripled the effectiveness of treatment of this dangerous disease, which can be fatal. Classical therapy gives the desired result only a third of patients. The novelty medics tested on a group of 30 volunteers with this diagnosis.

"Now in this group - 30 patients, mostly with generalized stages of the disease (when the disease has gone beyond one focus). We did not have a special selection, some kind of selection by age. To date, 21 people have already completed therapy, the overall response rate was 95-100%. Nine patients are still in the process of therapy, eight of them have also achieved a complete response," said Professor of the Department of Hematology at the N.V. Sklifosov Institute of Clinical Medicine. Elena Baryakh, Professor of the Department of Hematology at the N.V. Sklifosovsky Institute of Clinical Medicine, Head of the Hematology and Chemotherapy Department of Municipal Clinical Hospital No. 52.

Diffuse B-cell large cell lymphoma (DBCL) is a malignant tumor in which uncontrolled division of tumor lymphocytes occurs in lymph nodes. It is considered one of the most aggressive and common forms among a large group of similar pathologies, which are called non-Hodgkin's lymphomas. The disease is characterized by many different clinical manifestations, which are very rapidly progressing. The average age of patients is 60 years.

Read more in the exclusive material "Izvestia":

At the head of the node: a new approach tripled the effectiveness of lymphoma treatment